The kinin system: Suggestions to broaden some prevailing concepts

International Immunopharmacology

Volumn 2, Issue 13-14, 2002, Pages 1741-1746

  Erdös, Ervin G ^a   Deddish, Peter A ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

Author keywords

ACE; Bradykinin; Kinin system

Indexed keywords

ANGIOTENSIN; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; KALLIDIN; KALLIDIN[1-9]; KALLIKREIN; KININ; KININASE; KININOGEN; NITRIC OXIDE; PREKALLIKREIN; PROSTAGLANDIN; RECEPTOR PROTEIN; BRADYKININ RECEPTOR;

AMINO TERMINAL SEQUENCE; ARTICLE; CARBOXY TERMINAL SEQUENCE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HUMAN; KALLIKREIN KININ SYSTEM; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEIN SECRETION; ENZYMOLOGY; KIDNEY; METABOLISM; PHYSIOLOGY; REVIEW;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BRADYKININ; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; KIDNEY; KININS; RECEPTORS, BRADYKININ;

EID: 0036892440     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(02)00166-2     Document Type: Article

References (30)

1. Bhoola K.D., Figueroa C.D., Worthy K. Bioregulation of kinins: kallikreins, kininogens, and kininases. Pharmacol. Rev. 44:1992;1-80.
2. Kaplan A.P., Joseph K., Silverberg M. Pathways for bradykinin formation and inflammatory disease. J. Allergy Clin. Immunol. 109(2):2002;195-209.
3. Yamada K., Erdös E.G. Kallikrein and prekallikrein of the isolated basolateral membrane of rat kidney. Kidney Int. 22:1982;331-337.
4. Schröder E. Structure-activity relationships of kinins. Erdös E.G. Handbook of experimental pharmacology. vol. XXV:1970;324-350 Springer, Berlin.
5. 1 receptors for kinins. Pharmacol. Rev. 50:1998;357-386.
6. Erdös E.G., Deddish P.A., Marcic B.M. Potentiation of bradykinin actions by ACE inhibitors. Trends Endocrinol. Metab. 10:1999;223-229.
7. Rubin B., Laffan R.J., Kotler D.G., O'Keefe E.H., Demaio D.A., Goldberg M.E. SQ14,225 (D-3-mercapto-2-methylpropanoyl-L-proline), a novel orally active inhibitor of angiotensin I-converting enzyme. J. Pharmacol. Exp. Ther. 204:1978;271-280.
8. Minshall R.D., Nedumgottil S.J., Igic R., Erdös E.G., Rabito S.F. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum. Peptides. 24:2000;1257-1264.
9. Auch-Schwelk W., Bossaller C., Claus M., Graf K., Gräfe M., Fleck E. ACE inhibitors are endothelium dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc. Res. 27:1993;312-317.
10. Erdös E.G. Perspectives on the early history of angiotensin-converting enzyme - recent follow-ups. Giles T.D. Angiotensin-converting enzyme (ACE): clinical and experimental insights. 2001;3-16 Health Care Communications, Fort Lee.
11. 2 receptor selective agonist which is not broken down by either kininase I or kininase II. Eur. J. Pharmacol. 155:1988;193-195.
12. 2 receptor. Hypertension. 39(2 Pt 2):2002;619-623.
13. 2 bradykinin receptor by ACE inhibitors. J. Biol. Chem. 275(21):2000;16110-16118.
14. Dixon M., Webb E.C. Chap. 4 Enzyme kinetics. Enzymes. 1964;69 Academic Press, New York.
15. Skidgel R.A., Engelbrecht S., Johnson A.R., Erdös E.G. Hydrolysis of substance P and neurotensin by converting enzyme and neutral endopeptidase. Peptides. 5(4):1984;769-776.
16. Erdös E.G. Kinins, the long march - a personal view. Cardiovasc. Res. 54(3):2002;485-491.
17. Soubrier F., Hubert C., Testus P., Nadaud S., Alhenc-Gelas F., Corvol P. Molecular biology of the angiotensin I converting enzyme: I. Biochemistry and structure of the gene. J. Hypertension. 11:1993;471-476.
18. Bernstein K.E., Martin B.M., Edwards A.S., Bernstein E.A. Mouse angiotensin-converting enzyme is a protein composed of two homologous domains. J. Biol. Chem. 264:1989;11945-11951.
19. Soubrier F., Alhenc-Gelas F., Hubert C., Allegrini J., John M., Tregear G.et al. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc. Natl. Acad. Sci. U. S. A. 85:1988;9386-9390.
20. Williams T.A., Barnes K., Kenny A.J., Turner A.J., Hooper N.M. A comparison of the zinc contents and substrate specificities of the endothelial and testicular forms of porcine angiotensin converting enzyme and the preparation of isoenzyme-specific antisera. Biochem. J. 288(Pt 3):1992;875-881.
21. 2 receptor is activated by kallikrein and other serine proteases. Mol. Pharmacol. 58:2000;828-836.
22. 1 receptor. J. Biol. Chem. 277(19):2002;16847-16852.
23. Berne R.M., Levy M.N. Cardiovascular physiology. 2nd ed. 1972;C.V. Mosby, St. Louis.
24. Wooldridge D., Spragg J., Austen K.F. Interaction of Hageman-factor-dependent systems with the complement sequence. Pisano J.J., Austen K.F. Chemistry and biology of the kallikrein-kinin system in health and disease. 1976;221 U.S. Dept. of Health, Education and Welfare, St. Louis.
25. Hecker M., Pörsti K., Bara A.T., Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. Br. J. Pharmacol. 111:1994;238-244.
26. 2 receptors and ACE in CHO cells. Circ. Res. 81:1997;848-856.
27. 2 receptor. Hypertension. 33:1999;835-843.
28. Dendorfer A., Reibetamann S., Wolfrum S., Raasch W., Dominiak P. Potentiation of kinin analogues by ramiprilat is exclusively related to their degradation. Hypertension. 38(1):2001;142-146.
29. Mombouli J.V., Ballard K.D., Vanhoutte P.M. Kininase-independent potentiation of endothelium-dependent relaxations to kinins by converting enzyme inhibitor perindoprilat. Acta Pharmacol. Sin. 23(3):2002;203-207.
30. 2 receptor in the rabbit jugular vein: modulation of contractile response to bradykinin. Can. J. Physiol. Pharmacol. 80(2):2002;153-163.